Natalie Dickson, MD, president and chief strategy officer of Tennessee Oncology, discusses challenges for Tennessee Oncology and community oncology in general.
Natalie Dickson, MD, president and chief strategy officer of Tennessee Oncology, discusses government policy changes, utilization management, and other challenges for oncology care.
Transcript
What are some of the biggest challenges ahead for Tennessee Oncology specifically and for community oncology more broadly over the next several years?
Government policy changes and the burden of utilization management remain our biggest risk and challenge. Government policy changes can have sweeping effects on our reimbursement, such as the recently abandoned most-favored nation policy and the recent update on the in-office ancillary services exception. Utilization management—including things like step edits, prior authorization, formulary control—these remain really burdensome for practices, especially practices like ours who are already investing in and adherent to evidence-based clinical pathways. It's really important for community oncology to continue to advocate through CORe [Clinical Oncology Research system] and our specialty societies.
But we face many more challenges. PBMs [pharmacy benefit managers] redirecting patients away from our in-practice pharmacies prevent our patients from benefiting from our practice's compliance and toxicity monitoring. Obtaining access to real-time patient data is challenging, but it's really necessary to be able to participate successfully in value-based care programs and it is critical if a practice is taking on downside risks. And then don't forget the cost of a data warehouse. This is often prohibitive for small practices. Practices are being bombarded by a multitude of technology and service vendors, and it's hard to evaluate and determine their value, and many practices don't have the expertise to take this on. Tennessee Oncology is able to leverage the expertise of OneOncology to help in this regard.
And then, of course, there are new players on the market. Some of them pose some level of competition and others just increase the complexity of the management of our cancer patients; so things like infusion centers or pathology groups that are vying for access to a patient's tissue.
But despite all this, if we remain patient focused and true to our mission, and we remain engaged in health policy reform, I am confident that community oncology will weather the storm and the many challenges to come.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Survey Finds Slow Start on CMS Interoperability Rule Implementation
April 10th 2025With deadlines looming in 2026 and 2027 for compliance with the CMS Advancing Interoperability and Improving Prior Authorization Final Rule, a survey indicates a concerning lack of readiness among payers and providers to meet the new requirements for data sharing.
Read More